8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jan 11, 2010)

Filed January 11, 2010For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) filed a Form 8-K on January 11, 2010, reporting key financial and operational updates as of December 31, 2009. The company provided preliminary estimates for its 2009 net loss, cash position, outstanding shares, and convertible notes. This filing serves to inform investors of Vertex's financial standing at the close of the fiscal year. While specific figures for the net loss are not detailed within the 8-K itself, the press release referenced as Exhibit 99.1 contains these estimated results. Investors can look to this press release for detailed performance metrics and a snapshot of the company's capitalization, which are crucial for understanding its financial health and forward-looking prospects.

Key Highlights

  • 1Vertex Pharmaceuticals filed a Form 8-K on January 11, 2010, reporting preliminary financial data.
  • 2The report includes estimated 2009 net loss figures.
  • 3It provides an estimated balance of cash, cash equivalents, and marketable securities as of December 31, 2009.
  • 4Outstanding shares of capital stock as of December 31, 2009, are reported.
  • 5The principal amount of convertible subordinated notes outstanding as of December 31, 2009, is disclosed.
  • 6The information was disseminated via a press release dated January 10, 2010, attached as Exhibit 99.1.
  • 7This 8-K is primarily an informational filing, referencing external data rather than providing detailed financial statements within the report itself.

Frequently Asked Questions

The main purpose of this Form 8-K filing is to provide investors with an update on Vertex Pharmaceuticals' estimated financial performance and capitalization as of the end of 2009, primarily through a referenced press release.

The specific financial results, including the estimated 2009 net loss and cash balance, are detailed in the press release dated January 10, 2010, which is attached as Exhibit 99.1 to this Form 8-K filing.

The filing provides the estimated number of outstanding shares of capital stock and the principal amount of convertible subordinated notes as of December 31, 2009, offering insight into the company's capitalization.

No, this particular 8-K filing does not contain detailed financial statements. It serves as a notification of significant events and refers investors to an attached press release for the specific financial information.